Cost-Benefit Analysis
Salt substitution at age 40 years cost-effective for high-risk adults with prehypertension
Salt substitution intervention beginning at age 40 years was cost-effective among Chinese adults with prehypertension compared with antihypertensive drug treatment alone, according to findings published in Hypertension.
Insertable cardiac monitor for atrial fibrillation detection likely cost-effective in US
Insertable cardiac monitoring for atrial fibrillation detection was found to be cost-effective, especially among high-risk patients, according to an economic analysis of the STROKE AF trial presented at the International Stroke Conference.
Prehospital rule-out of NSTEACS cost-effective vs. ED admission at 1 year
Prehospital rule-out of non-ST-segment elevation ACS with risk assessment and a single troponin test led to lower health care cost with similarly low 1-year outcomes vs. rule-out in the ED, results of the ARTICA trial show.
PCI not cost-effective in patients with CAD, heart failure vs. optimal medical therapy
PHILADELPHIA — In patients with CAD and ischemic left ventricular dysfunction, PCI did not add significantly more quality-adjusted life-years and cost significantly more compared with optimal medical therapy alone, a speaker reported.
Intensive medication optimization cost-effective in patients hospitalized with HFrEF
PHILADELPHIA — An intensive medication optimization program for patients hospitalized with HF with reduced ejection fraction would be cost-effective, researchers reported at the American Heart Association Scientific Sessions.
Workplace mental health program linked to benefits for employees, employers
Enrollment in a workplace mental health program was linked to improvements in symptoms of anxiety and depression and resulted in positive return on investment for employers, according to a study published in JAMA Network Open.
Pharma-funded studies far more likely to find oncology drugs cost-effective
Studies funded by pharmaceutical companies appeared significantly more likely to find oncology drugs cost-effective than studies without such funding, according to results of a cross-sectional study published in JAMA Network Open.
Screening first-degree relatives of patients with bicuspid aortic valves cost-effective
A strategy of screening first-degree relatives of patients with bicuspid aortic valves was cost-effective and cost-saving, researchers reported at the European Society of Cardiology Congress.
Icosapent ethyl dominant vs. standard care in cost per QALY
PHILADELPHIA — Icosapent ethyl for patients at high CV risk conferred cost-savings in-trial and during patients’ lifetime, according to findings presented at the American Heart Association Scientific Sessions.
ICER report: Icosapent ethyl offers ‘high long-term value’
Amarin announced that the Institute for Clinical and Economic Review issued its final report on the cost-effectiveness of icosapent ethyl and found that the medication has “high long-term value for money.”